{"pmid":32174053,"title":"False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases.","text":["False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases.","The epidemic of 2019 novel coronavirus, later named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still gradually spreading worldwide. The nucleic acid test or genetic sequencing serves as the gold standard method for confirmation of infection, yet several recent studies have reported false-negative results of real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Here, we report two representative false-negative cases and discuss the supplementary role of clinical data with rRT-PCR, including laboratory examination results and computed tomography features. Coinfection with SARS-COV-2 and other viruses has been discussed as well.","Korean J Radiol","Li, Dasheng","Wang, Dawei","Dong, Jianping","Wang, Nana","Huang, He","Xu, Haiwang","Xia, Chen","32174053"],"abstract":["The epidemic of 2019 novel coronavirus, later named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still gradually spreading worldwide. The nucleic acid test or genetic sequencing serves as the gold standard method for confirmation of infection, yet several recent studies have reported false-negative results of real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Here, we report two representative false-negative cases and discuss the supplementary role of clinical data with rRT-PCR, including laboratory examination results and computed tomography features. Coinfection with SARS-COV-2 and other viruses has been discussed as well."],"journal":"Korean J Radiol","authors":["Li, Dasheng","Wang, Dawei","Dong, Jianping","Wang, Nana","Huang, He","Xu, Haiwang","Xia, Chen"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32174053","week":"202012|Mar 16 - Mar 22","doi":"10.3348/kjr.2020.0146","keywords":["False-negative results","COVID-19","Computed tomography","Laboratory examination","SARS-COV-2","rRT-PCR"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1661456248857427969,"score":6.7365713,"similar":[{"pmid":32172228,"title":"Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","text":["Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance.","Clin Chem Lab Med","Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario","32172228"],"abstract":["A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32172228","week":"202012|Mar 16 - Mar 22","doi":"10.1515/cclm-2020-0285","keywords":["COVID-19","coronavirus","diagnosis","reverse transcription polymerase chain reaction (RT-PCR)"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1661518929237901312,"score":232.41284},{"pmid":32132196,"title":"Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens.","text":["Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens.","On 31(st) December 2019, the World Health Organization was informed of a cluster of cases of pneumonia of unknown etiology in Wuhan, China. Subsequent investigations identified a novel coronavirus, now named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from the affected patients. Highly sensitive and specific laboratory diagnostics are important for controlling the rapidly evolving SARS-CoV-2-associated Coronavirus Disease 2019 (COVID-19) epidemic. In this study, we developed and compared the performance of three novel real-time RT-PCR assays targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S), and nucleocapsid (N) genes of SARS-CoV-2 with that of the reported RdRp-P2 assay which is used in >30 European laboratories. Among the three novel assays, the COVID-19-RdRp/Hel assay had the lowest limit of detection in vitro (1.8 TCID50/ml with genomic RNA and 11.2 RNA copies/reaction with in vitro RNA transcripts). Among 273 specimens from 15 patients with laboratory-confirmed COVID-19 in Hong Kong, 77 (28.2%) were positive by both the COVID-19-RdRp/Hel and RdRp-P2 assays. The COVID-19-RdRp/Hel assay was positive for an additional 42 RdRd-P2-negative specimens [119/273 (43.6%) vs 77/273 (28.2%), P<0.001], including 29/120 (24.2%) respiratory tract specimens and 13/153 (8.5%) non-respiratory tract specimens. The mean viral load of these specimens was 3.21x10(4) RNA copies/ml (range, 2.21x10(2) to 4.71x10(5) RNA copies/ml). The COVID-19-RdRp/Hel assay did not cross-react with other human-pathogenic coronaviruses and respiratory pathogens in cell culture and clinical specimens, whereas the RdRp-P2 assay cross-reacted with SARS-CoV in cell culture. The highly sensitive and specific COVID-19-RdRp/Hel assay may help to improve the laboratory diagnosis of COVID-19.","J Clin Microbiol","Chan, Jasper Fuk-Woo","Yip, Cyril Chik-Yan","To, Kelvin Kai-Wang","Tang, Tommy Hing-Cheung","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tsoi, Hoi-Wah","Choi, Garnet Kwan-Yue","Tam, Anthony Raymond","Cheng, Vincent Chi-Chung","Chan, Kwok-Hung","Tsang, Owen Tak-Yin","Yuen, Kwok-Yung","32132196"],"abstract":["On 31(st) December 2019, the World Health Organization was informed of a cluster of cases of pneumonia of unknown etiology in Wuhan, China. Subsequent investigations identified a novel coronavirus, now named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from the affected patients. Highly sensitive and specific laboratory diagnostics are important for controlling the rapidly evolving SARS-CoV-2-associated Coronavirus Disease 2019 (COVID-19) epidemic. In this study, we developed and compared the performance of three novel real-time RT-PCR assays targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S), and nucleocapsid (N) genes of SARS-CoV-2 with that of the reported RdRp-P2 assay which is used in >30 European laboratories. Among the three novel assays, the COVID-19-RdRp/Hel assay had the lowest limit of detection in vitro (1.8 TCID50/ml with genomic RNA and 11.2 RNA copies/reaction with in vitro RNA transcripts). Among 273 specimens from 15 patients with laboratory-confirmed COVID-19 in Hong Kong, 77 (28.2%) were positive by both the COVID-19-RdRp/Hel and RdRp-P2 assays. The COVID-19-RdRp/Hel assay was positive for an additional 42 RdRd-P2-negative specimens [119/273 (43.6%) vs 77/273 (28.2%), P<0.001], including 29/120 (24.2%) respiratory tract specimens and 13/153 (8.5%) non-respiratory tract specimens. The mean viral load of these specimens was 3.21x10(4) RNA copies/ml (range, 2.21x10(2) to 4.71x10(5) RNA copies/ml). The COVID-19-RdRp/Hel assay did not cross-react with other human-pathogenic coronaviruses and respiratory pathogens in cell culture and clinical specimens, whereas the RdRp-P2 assay cross-reacted with SARS-CoV in cell culture. The highly sensitive and specific COVID-19-RdRp/Hel assay may help to improve the laboratory diagnosis of COVID-19."],"journal":"J Clin Microbiol","authors":["Chan, Jasper Fuk-Woo","Yip, Cyril Chik-Yan","To, Kelvin Kai-Wang","Tang, Tommy Hing-Cheung","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tsoi, Hoi-Wah","Choi, Garnet Kwan-Yue","Tam, Anthony Raymond","Cheng, Vincent Chi-Chung","Chan, Kwok-Hung","Tsang, Owen Tak-Yin","Yuen, Kwok-Yung"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32132196","week":"202010|Mar 02 - Mar 08","doi":"10.1128/JCM.00310-20","source":"PubMed","locations":["P<0.001]","Wuhan","RdRd","European","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1661359647714443264,"score":184.16437},{"pmid":32104917,"title":"Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis.","text":["Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis.","The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (SARS-Cov-2) nucleic acid RT-PCR test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay which can detect IgM and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at 8 different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories. This article is protected by copyright. All rights reserved.","J Med Virol","Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng","32104917"],"abstract":["The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (SARS-Cov-2) nucleic acid RT-PCR test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay which can detect IgM and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at 8 different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32104917","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25727","keywords":["COVID-19","Lateral flow immunoassay","Point-of-Care Testing","SARS-CoV-2 Virus Infection","fingerstick blood","rapid IgM-IgG Combined test"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647547719681,"score":157.78027},{"pmid":32162081,"title":"Chest computed tomography in children with COVID-19 respiratory infection.","text":["Chest computed tomography in children with COVID-19 respiratory infection.","BACKGROUND: Infection with COVID-19 is currently rare in children. OBJECTIVE: To describe chest CT findings in children with COVID-19. MATERIALS AND METHODS: We studied children at a large tertiary-care hospital in China, during the period from 28 January 2019 to 8 February 2020, who had positive reverse transcriptase polymerase chain reaction (RT-PCR) for COVID-19. We recorded findings at any chest CT performed in the included children, along with core clinical observations. RESULTS: We included five children from 10 months to 6 years of age (mean 3.4 years). All had had at least one CT scan after admission. Three of these five had CT abnormality on the first CT scan (at 2 days, 4 days and 9 days, respectively, after onset of symptoms) in the form of patchy ground-glass opacities; all normalised during treatment. CONCLUSION: Compared to reports in adults, we found similar but more modest lung abnormalities at CT in our small paediatric cohort.","Pediatr Radiol","Li, Wei","Cui, Huaqian","Li, Kunwei","Fang, Yijie","Li, Shaolin","32162081"],"abstract":["BACKGROUND: Infection with COVID-19 is currently rare in children. OBJECTIVE: To describe chest CT findings in children with COVID-19. MATERIALS AND METHODS: We studied children at a large tertiary-care hospital in China, during the period from 28 January 2019 to 8 February 2020, who had positive reverse transcriptase polymerase chain reaction (RT-PCR) for COVID-19. We recorded findings at any chest CT performed in the included children, along with core clinical observations. RESULTS: We included five children from 10 months to 6 years of age (mean 3.4 years). All had had at least one CT scan after admission. Three of these five had CT abnormality on the first CT scan (at 2 days, 4 days and 9 days, respectively, after onset of symptoms) in the form of patchy ground-glass opacities; all normalised during treatment. CONCLUSION: Compared to reports in adults, we found similar but more modest lung abnormalities at CT in our small paediatric cohort."],"journal":"Pediatr Radiol","authors":["Li, Wei","Cui, Huaqian","Li, Kunwei","Fang, Yijie","Li, Shaolin"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32162081","week":"202011|Mar 09 - Mar 15","doi":"10.1007/s00247-020-04656-7","keywords":["COVID-19","Child","Computed tomography","Coronavirus","Pneumonia","Viral"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1661359647898992641,"score":153.77342},{"pmid":32133832,"title":"[Potential false-positive rate among the 'asymptomatic infected individuals' in close contacts of COVID-19 patients].","text":["[Potential false-positive rate among the 'asymptomatic infected individuals' in close contacts of COVID-19 patients].","Objective: As the prevention and control of COVID-19continues to advance, the active nucleic acid test screening in the close contacts of the patients has been carrying out in many parts of China. However, the false-positive rate of positive results in the screening has not been reported up to now. But to clearify the false-positive rate during screening is important in COVID-19 control and prevention. Methods: Point values and reasonable ranges of the indicators which impact the false-positive rate of positive results were estimated based on the information available to us at present. The false-positive rate of positive results in the active screening was deduced, and univariate and multivariate-probabilistic sensitivity analyses were performed to understand the robustness of the findings. Results: When the infection rate of the close contacts and the sensitivity and specificity of reported results were taken as the point estimates, the positive predictive value of the active screening was only 19.67%, in contrast, the false-positive rate of positive results was 80.33%. The multivariate-probabilistic sensitivity analysis results supported the base-case findings, with a 75% probability for the false-positive rate of positive results over 47%. Conclusions: In the close contacts of COVID-19 patients, nearly half or even more of the 'asymptomatic infected individuals' reported in the active nucleic acid test screening might be false positives.","Zhonghua Liu Xing Bing Xue Za Zhi","Zhuang, G H","Shen, M W","Zeng, L X","Mi, B B","Chen, F Y","Liu, W J","Pei, L L","Qi, X","Li, C","32133832"],"abstract":["Objective: As the prevention and control of COVID-19continues to advance, the active nucleic acid test screening in the close contacts of the patients has been carrying out in many parts of China. However, the false-positive rate of positive results in the screening has not been reported up to now. But to clearify the false-positive rate during screening is important in COVID-19 control and prevention. Methods: Point values and reasonable ranges of the indicators which impact the false-positive rate of positive results were estimated based on the information available to us at present. The false-positive rate of positive results in the active screening was deduced, and univariate and multivariate-probabilistic sensitivity analyses were performed to understand the robustness of the findings. Results: When the infection rate of the close contacts and the sensitivity and specificity of reported results were taken as the point estimates, the positive predictive value of the active screening was only 19.67%, in contrast, the false-positive rate of positive results was 80.33%. The multivariate-probabilistic sensitivity analysis results supported the base-case findings, with a 75% probability for the false-positive rate of positive results over 47%. Conclusions: In the close contacts of COVID-19 patients, nearly half or even more of the 'asymptomatic infected individuals' reported in the active nucleic acid test screening might be false positives."],"journal":"Zhonghua Liu Xing Bing Xue Za Zhi","authors":["Zhuang, G H","Shen, M W","Zeng, L X","Mi, B B","Chen, F Y","Liu, W J","Pei, L L","Qi, X","Li, C"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32133832","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112338-20200221-00144","keywords":["COVID-19","Close contacts","False-positive","Nucleic acid test","Screening"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1661359647725977600,"score":150.56973}]}